Finnish Red Cross Licenses GeneGo Products

ST. JOSEPH, Mich., Jan. 22 /PRNewswire/ -- GeneGo, Inc., the leading
systems biology tools company, announced today that the Finnish Red Cross
Blood Service has licensed GeneGo's bioinformatics and chemoinformatics suites
MetaCore(TM) and MetaDrug(TM), respectively, to be used in a variety of
research and clinical projects
"The entrepreneur knowledgebase behind the merged platform is impressive
in the areas of cell adhesion and immunology, which is essential in blood
transfusion field," said docent Jukka Partanen, research director at the FRC
Blood Service R&D.
In a joint effort with the Finnish hospitals, FRC Blood Service is
collecting clinical information from nearly 70% of the patients receiving
blood transfusions in the country, to optimize the blood component usage far
beyond 2000 annual diagnoses. Beside the blood group and cell type analysis in
disease and pregnancy, we are working with tissue typing of donors and
recipients in organ, bone marrow and cord blood and bone marrow stem cell
replacement transplantations.
"In the market, we have not found any other manually curated platform
where multiple parallel omics data could be submitted in a batch mode in such
a systems medicine fashion. We are delighted that the curation does not ignore
the non-English journals and reviews patent literature as well. The principle
of taking only causality and not mere association into account is critical in
the era of NLP text mining servers and HTS data flood," said Jukka Partanen.
"We are very pleased to be working with such a prestigious organization,"
said Julie Bryant VP of Business development for GeneGo. "Disease-centric
systems medicine is a natural and logical step in the development of our tools
and databases and we are excited to see healthcare organizations such as
Finnish Red Cross using it in such practical and important way."
About GeneGo
GeneGo develops systems biology technology for life science research. The
original computational MetaDiscovery(TM) platform allows an integration and
expert analysis of different kinds of experimental data (mRNA expression,
proteomics, metabolomics, microRNA assays and other phenotypic data) and
relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within
the framework of curated biological pathways and networks. GeneGo's flagship
product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of
target selection and validation, identification of biomarkers for disease
states and toxicology. The second product, MetaDrug 5.0(TM) is designed for
prediction of human metabolism, toxicity and biological effects for novel
small molecules compounds. MetaBase(TM) represents the knowledge base for
MetaCore. For more information, please visit the company's web site at
http://www.genego.com
MetaCore(TM), MetaBase(TM) MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM),
MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo,
Inc.
SOURCE GeneGo, Inc.

Julie Bryant, VP Business Development and Marketing of GeneGo, Inc.,
+1-858-756-7996, julie@genego.com